ReviewFrontiers in immunology2026
CD39 in the pathogenesis of neuro-Behçet disease: is it an immune regulator marker?
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuro-Behçet's disease (NBD) is a severe neurological manifestation of Behçet's disease (BD), a multisystemic inflammatory vasculitis affecting multiple organs. NBD presents complex immunopathological features involving both innate and adaptive immune responses. CD39 (ectonucleoside triphosphate diphosphohydrolase-1, ENTPD1), an ectoenzyme expressed on various immune cells, has emerged as a critical regulator of inflammation through its role in hydrolyzing extracellular ATP to immunosuppressive adenosine. This mini-review explores the role of CD39 in modulating neuroinflammation in NBD, focusing on its function in immune cell subsets, its dual role in inflammation and regulation, and its potential as a therapeutic target. It synthesizes the role of CD39 in neuroinflammatory disorders, with a specific focus on Neuro-Behçet's Disease (NBD). We examine the dual role of CD39 expression in driving inflammation and immune regulation, and highlighting its potential as a therapeutic target.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.